Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis

Maria, A.; Toupet, Karine; Maumus, Marie; Fonteneau, Gilles; Quellec, A. Le; Jørgensen, Christian; Guilpain, Philippe; Noël, Danièle

doi:10.1016/j.jaut.2016.03.013

Cited by 100 publications

(92 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, it has been demonstrated in mice that adipose tissue‐derived human MSC were significantly more efficient in reducing skin fibrosis as compared to bone marrow‐derived MSC. This difference was related to a stronger reduction of TNFα and IL‐1β as well as an enhanced ratio of MMP1/TIMP1 in skin and lung tissues when treated with adipose tissue‐ as compared to treatment with bone marrow‐derived MSC .…”

Section: Clinical Usementioning

confidence: 99%

Mammalian MSC from selected species: Features and applications

et al. 2017

View full text Add to dashboard Cite

Mesenchymal stromal/stem cells (MSC) are promising candidates for cellular therapy of different diseases in humans and in animals. Following the guidelines of the International Society for Cell Therapy, human MSC may be identified by expression of a specific panel of cell surface markers (CD105+, CD73+, CD90+, CD34-, CD14-, or CD11b-, CD79- or CD19-, HLA-DR-). In addition, multiple differentiation potential into at least the osteogenic, adipogenic, and chondrogenic lineage is a main criterion for MSC definition. Human MSC and MSC of a variety of mammals isolated from different tissues meet these criteria. In addition to the abovementioned, they express many more cell surface markers. Yet, these are not uniquely expressed by MSC. The gross phenotypic appearance like marker expression and differentiation potential is similar albeit not identical for MSC from different tissues and species. Similarly, MSC may feature different biological characteristics depending on the tissue source and the isolation and culture procedures. Their versatile biological qualities comprising immunomodulatory, anti-inflammatory, and proregenerative capacities rely largely on the migratory and secretory capabilities of MSC. They are attracted to sites of tissue lesion and secrete factors to promote self-repair of the injured tissue. This is a big perspective for clinical MSC applications in both veterinary and human medicine. Phase I/II clinical trials have been initiated to assess safety and feasibility of MSC therapies in acute and chronic disease settings. Yet, since the mode of MSC action in a specific disease environment is still unknown at large, it is mandatory to unravel the response of MSC from a given source onto a specific disease environment in suitable animal models prior to clinical applications. © 2017 International Society for Advancement of Cytometry.

show abstract

Section: Clinical Usementioning

confidence: 99%

Mammalian MSC from selected species: Features and applications

et al. 2017

View full text Add to dashboard Cite

show abstract

“…As a result, MSCs escape recognition by effector CD4 + T cells and avoid an allogenic rejection response . However, it was also reported that transient interaction between ASC/MSCs and immune cells is enough to exert their regulatory role . Thus, it is not necessary for ASC/MSCs to escape from rejection to exert a regulatory effect on inflammation‐dependent tissue fibrosis.…”

Section: Discussionmentioning

confidence: 99%

“…42 However, it was also reported that transient interaction between ASC/MSCs and immune cells is enough to exert their regulatory role. 14 43 In addition, it was reported that allo-MSCs are superior to auto-MSCs in the clinical trial for non-ischemic dilated cardiomyopathy. 44 To date, ASCs have been reported to show effectiveness in human clinical trials for heart failure, renal failure, and liver cirrhosis.…”

Section: Discussionmentioning

confidence: 99%

“…Adipose‐derived stromal/stem cells (ASCs) have also been shown to play an important role in immune regulatory function . In addition, ASCs exhibit more potent immunomodulatory effects compared with bone marrow‐derived MSCs (BM‐MSCs) . Thus, the use of ASCs is a more reasonable treatment strategy for patients with autoimmune diseases, when compared with BM‐MSCs.…”

Section: Introductionmentioning

confidence: 99%

“…13 In addition, ASCs exhibit more potent immunomodulatory effects compared with bone marrow-derived MSCs (BM-MSCs). 14 Thus, the use of ASCs is a more reasonable treatment strategy for patients with autoimmune diseases, when compared with BM-MSCs. Moreover, cell-based ASC treatment is superior to conventional immunosuppressive therapy in terms of side effects, such as infection and toxicity.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adipose‐derived stromal/stem cells successfully attenuate the fibrosis of scleroderma mouse models

et al. 2019

View full text Add to dashboard Cite

Aim Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and lung fibrosis. Although SSc has a high mortality risk, an effective treatment for the disease has not been established yet. Mesenchymal stromal/stem cells (MSCs) are multipotential nonhematopoietic progenitor cells that have the ability to regulate immune responses. Adipose‐derived stromal/stem cells (ASCs), one of the types of MSCs, have the advantage of accessibility and potent immunomodulatory effects when compared with other MSCs, such as bone marrow‐derived MSCs. This study aimed to investigate the antifibrotic effect of ASCs in scleroderma mouse models, including bleomycin‐induced scleroderma and sclerodermatous chronic graft‐versus‐host disease (Scl‐cGVHD) models. Method ASCs were intravenously administered to a bleomycin‐induced scleroderma or Scl‐cGVHD model on day 0. We compared the skin and lung fibrosis of scleroderma model mice between the ASC‐treated group and control group. Results Administration of ASCs attenuated the skin and lung fibrosis of bleomycin‐induced scleroderma and Scl‐cGVHD model mice compared to that in the control mice. Immunohistochemical staining showed that ASCs suppressed the infiltration of CD4+, CD8+ T cells and macrophages into the dermis of bleomycin model mice compared to that in control mice. In addition, ASCs attenuated the messenger RNA expression of collagen and fibrogenic cytokines, such as interleukin (IL)‐6 and IL‐13, in the skin of bleomycin model mice. ASCs also reduced the frequency of fibrogenic cytokine‐producing CD4+ T cells and effector B cells in the spleen of bleomycin model mice. Conclusion ASCs could prove to be a potential therapeutic agent for use in patients with SSc.

show abstract